688075.SH
安旭生物
SSE · Healthcare · Medical - Specialties · CN
CNY 29.08
−1.59%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 407.2M | 451.3M | 540.7M | 503.4M | 6.2B |
| Cost of Revenue | 235.1M | 259.5M | 329.3M | 290.4M | 1.6B |
| Gross Profit | 172.1M | 191.8M | 211.4M | 212.9M | 4.6B |
| Operating Expenses | |||||
| R&D Expense | 69.4M | 78.7M | 101.1M | 105.3M | 329.1M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 57.3M | 54.6M | 54.1M | 66.5M | 74.7M |
| Selling & Marketing Expense | 46.2M | 52.5M | 49.3M | 42.8M | 493.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 295.1M | 271.7M | 172.8M | 152.3M | 412.6M |
| Cost and Expenses | 530.2M | 531.1M | 502.1M | 442.7M | 2.0B |
| Operating Income (EBIT) | 20.6M | 69.6M | 207.6M | 167.5M | 3.5B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 25.9M | 74.9M | 210.6M | 143.8M | 3.5B |
| Income Tax Expense | 1.3M | 5.7M | 18.4M | 2.9M | 475.3M |
| Bottom Line | |||||
| Net Income | 25.0M | 69.4M | 192.3M | 141.6M | 3.0B |
| Earnings from Cont. Ops | 24.6M | 69.2M | 192.2M | — | 3.0B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 25.0M | 69.4M | 192.3M | 141.6M | 3.0B |
| Per Share | |||||
| Basic EPS | CN¥0.20 | CN¥0.55 | CN¥1.51 | CN¥1.11 | CN¥23.95 |
| Diluted EPS | CN¥0.20 | CN¥0.55 | CN¥1.51 | CN¥1.11 | CN¥23.95 |
| Revenue Per Share | CN¥3.14 | CN¥3.58 | CN¥4.25 | CN¥3.95 | CN¥48.50 |
| Shares | |||||
| Basic Shares Outstanding | 129.5M | 126.2M | 127.3M | 127.5M | 127.1M |
| Diluted Shares Outstanding | 129.5M | 126.2M | 127.3M | 127.5M | 127.1M |
| Profitability Metrics | |||||
| EBITDA | — | 120.9M | 261.8M | 232.3M | 3.6B |
| D&A | — | 51.4M | 54.2M | 64.8M | 41.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026